interferon beta-1a

This medicine is authorised for use in the European Union.


Rebif is a medicine used to treat patients with relapsing multiple sclerosis (MS). MS is a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. Relapsing MS is the type of MS where the patient has attacks (relapses) between periods with no symptoms. Rebif’s effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS) that is not relapsing.

Rebif can also be used in patients who have had a single attack of demyelination accompanied by inflammation. It is used when the patient is considered to be at high risk of developing MS. Before using Rebif, doctors need to exclude other causes for the symptoms.

Rebif contains the active substance interferon beta-1a.

This EPAR was last updated on 07/01/2021

Authorisation details

Product details
Agency product number
Active substance
interferon beta-1a
International non-proprietary name (INN) or common name
interferon beta-1a
Therapeutic area (MeSH)
Multiple Sclerosis
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Europe B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Gustav Mahlerplein 102
Ito Toren
1082 MA Amsterdam
The Netherlands

Product information

09/12/2020 Rebif - EMEA/H/C/000136 - IB/0148


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Rebif is indicated for the treatment of:

  • patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;
  • patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years.

Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity.

Assessment history

How useful was this page?

Add your rating
2 ratings